Zhonghui Bio-B (02627): The adsorbed tetanus toxoid vaccine obtained IND approval from the China Drug Administration

Zhitongcaijing · 1d ago

Zhitong Finance App News, Zhonghui Bio-B (02627) issued an announcement. The Drug Evaluation Center of the State Drug Administration (China Drug Evaluation Center) approved the new drug clinical trial (IND) application for adsorbed tetanus toxoid vaccine (adsorbed tetanus vaccine) candidate products independently developed by the Group on November 12, 2026.

Tetanus is an acute specific infection caused by Clostridium tetanus spores entering the body through a wound. It can be very dangerous or even fatal. Spores can be found everywhere in the environment, particularly in soil, ash, animal and human feces, as well as skin and rusted tool surfaces such as nails, needles, and barbed wire. Prevention of tetanus mainly relies on proper wound management and immunization: primary prevention through active immunization involves vaccination containing tetanus toxoid to develop long-term immunity; secondary prevention is passive immunity, which uses immediate immune effects such as tetanus antitoxin (TAT) or immunoglobulin for acute cases. The Group's adsorbed tetanus vaccine is designed to induce the body to produce protective antitoxic antibodies through immunization. The board of directors believes that the approval of the IND application by the China Drug Review Center marks important progress in the Group's research and development in the field of traditional vaccines and lays the foundation for the development of clinical research on this candidate product.